Opthea reports Fiscal Year 2022 Results and Highlights
Filed with ASX · · 2 pages · English
Melbourne, Australia; August 30, 2022– Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today reported financial results for the fiscal year ended June 30, 2022and provided an overview of recent progress. “Over the past year, Opthea has focused on advancing our Phase 3 clinical tr
Story so far
Earlier from Opthea
- Opthea Share Purchase Plan
- Form 6-K with SEC
- Opthea Successfully Closes Well Supported US$90m Financing
- Opthea secures up to US$170m in non-dilutive financing
- Opthea Data for OPT-302 for PCV presented at ARVO 2022
Later from Opthea
- Completion of Share Purchase Plan
- Chairmans Address to Shareholders
- Opthea Corporate Presentation - San Francisco Jan 2023
- Opthea Ph2b Trial Results with OPT-302 published in Journal
- Response to ASX Query
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea